
Medicenna is a clinical-stage immunotherapy company developing engineered interleukins—IL-2, IL-4 and IL-13 Superkines via directed evolution—rather than conventional molecules.
medicenna.comCrawled Nov 15, 2026
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines
Master the Signal. Navigate Complexity. Create Cures.
Medicenna reports **40% objective response rate (ORR)** in **ABILITY-1**, a trial testing **MDNA11**—a novel IL-2 Superkine—on **gastrointestinal cancer patients** whose tumors carry biomarkers and have failed standard therapies. The study evaluates MDNA11 alone or combined with **pembrolizumab** in advanced solid tumors resistant to approved treatments. Early findings highlight potential efficacy in biomarker-selected, treatment-refractory populations.
Medicenna Therapeutics completes enrollment for its global Phase 1/2 **ABILITY-1** trial of **MDNA11**, an immunotherapy candidate targeting cancer and autoimmune diseases. The company develops **Superkines™**, a proprietary platform. Medicenna will host a **key opinion leader (KOL) webinar** on November 10, 2026, to present updated study results.
Medicenna demonstrates that **MDNA209**, its engineered Superkine, blocks **CD122** and extends survival in preclinical autoimmune disease models. The therapy suppresses overactive immune cells by inhibiting **IL-2 and IL-15 signaling**, targeting inflammatory pathways. Early results suggest potential as a first-in-class treatment for autoimmune conditions.
Medicenna Therapeutics presents preclinical data on **MDNA209**, its cytokine-based **CD122 superantagonist**, at *The Promises of Treg and Interleukin-2 Therapies Conference* in Paris. The company, specializing in immunotherapy for cancer and autoimmune diseases, highlights MDNA209 as a potential first-in-class treatment. The presentation occurs during the October 21–24, 2026 event, showcasing early-stage research on its Superkines platform.
Medicenna presents topline Phase 1/2 ABILITY-1 trial results for its experimental therapy **MDNA11**, targeting patients with advanced or metastatic **gastrointestinal, endometrial, and melanoma cancers**. The oral presentation at **SITC 2026** highlights findings from expansion cohorts evaluating safety and efficacy in these cancer types. The study assesses MDNA11’s potential as a novel treatment option for refractory solid tumors.
Medicenna Therapeutics reports voting results from its October 1, 2026 annual and special shareholder meeting. The clinical-stage immunotherapy company focuses on developing **Superkines** for treating **cancer and autoimmune diseases**. Shareholders participated in decisions regarding company governance and strategic direction.